N-(3-Chloro-4-morpholinophenyl)-N'-hydroxyformimidamide (TS-011) is a selective 20-Hydroxyeicosatetraenoic acid synthesis inhibitor.

Administered at a dose of 0.3 mg/kg, TS-011 effectively inhibits the decrease in blood flow velocities observed at 1 and 7 hours post-reperfusion, as evidenced by significant statistical values (P<0.001), and prevents the acceleration of blood flow velocity at 24 hours after reperfusion (P<0.01). Additionally, this dosage of TS-011 substantially reduces the volume of infarcts by nearly 40% (P<0.05) and maintains microvascular perfusion areas, which are otherwise diminished in mice treated with a standard vehicle [1]. Furthermore, in a study involving 9 dogs experiencing delayed vasospasm, an acute intervention with TS-011 (1 mg/kg IV) markedly enlarged the basilar artery's diameter by 39%, illustrating a significant impact on vascular health [2].